Oncogene-Directed Alterations in Cancer Cell Metabolism
Tóm tắt
Từ khóa
Tài liệu tham khảo
Brodeur, 1984, Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage, Science, 224, 1121, 10.1126/science.6719137
Kohl, 1984, Activated expression of the N-myc gene in human neuroblastomas and related tumors, Science, 226, 1335, 10.1126/science.6505694
Park, 2004, Determination of binding constant of transcription factor myc-max/max-max and E-box DNA: the effect of inhibitors on the binding, Biochim. Biophys. Acta, 1670, 217, 10.1016/j.bbagen.2003.12.007
Nakagawara, 1987, N-myc oncogene amplification and catecholamine metabolism in children with neuroblastoma, Lancet, 1, 559, 10.1016/S0140-6736(87)90195-4
Nakagawara, 1990, Inverse correlation between N-myc amplification and catecholamine metabolism in children with advanced neuroblastoma, Surgery, 107, 43
Tonini, 1987, N-myc oncogene amplification and catecholamine metabolism in patients with neuroblastoma, Lancet, 2, 795, 10.1016/S0140-6736(87)92521-9
Pusch, 1997, Cellular targets for activation by c-Myc include the DNA metabolism enzyme thymidine kinase, DNA Cell Biol., 16, 737, 10.1089/dna.1997.16.737
Shim, 1997, c-Myc transactivation of LDH-A: implications for tumor metabolism and growth, Proc. Natl. Acad. Sci. U.S.A., 94, 6658, 10.1073/pnas.94.13.6658
Maya-Mendoza, 2015, Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress, Mol. Oncol., 9, 601, 10.1016/j.molonc.2014.11.001
Edmunds, 2014, c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate, J. Biol. Chem., 289, 25382, 10.1074/jbc.M114.580662
de la Cova, 2014, Supercompetitor status of Drosophila Myc cells requires p53 as a fitness sensor to reprogram metabolism and promote viability, Cell Metab., 19, 470, 10.1016/j.cmet.2014.01.012
Liu, 2012, Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC, Proc. Natl. Acad. Sci. U.S.A., 109, 8983, 10.1073/pnas.1203244109
Gao, 2009, c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism, Nature, 458, 762, 10.1038/nature07823
Mannava, 2008, Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells, Cell Cycle, 7, 2392, 10.4161/cc.6390
Shroff, 2015, MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism, Proc. Natl. Acad. Sci. U.S.A., 112, 6539, 10.1073/pnas.1507228112
Curtin, 2005, Distinct sets of genetic alterations in melanoma, N. Engl. J. Med., 353, 2135, 10.1056/NEJMoa050092
Neri, 1988, Analysis of RAS oncogene mutations in human lymphoid malignancies, Proc. Natl. Acad. Sci. U.S.A., 85, 9268, 10.1073/pnas.85.23.9268
Bacher, 2006, Implications of NRAS mutations in AML: a study of 2502 patients, Blood, 107, 3847, 10.1182/blood-2005-08-3522
Guo, 2013, Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation, Nat. Genet., 45, 1459, 10.1038/ng.2798
Agrawal, 2011, Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1, Science, 333, 1154, 10.1126/science.1206923
Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, 3, 11, 10.1038/nrc969
Pakala, 1988, Polyamine metabolism and interconversion in NIH 3T3 and ras-transfected NIH 3T3 cells, Cancer Res., 48, 3336
Chiarugi, 1989, Signal transduction in EJ-H-ras-transformed cells: de novo synthesis of diacylglycerol and subversion of agonist-stimulated inositol lipid metabolism, FEBS Lett., 252, 129, 10.1016/0014-5793(89)80904-4
Huang, 1988, Enhancement of inositol phospholipid metabolism and activation of protein kinase C in ras-transformed rat fibroblasts, J. Biol. Chem., 263, 17975, 10.1016/S0021-9258(19)81311-X
Milligan, 1989, Identification of the pertussis and cholera toxin substrates in normal and N-ras transformed NIH3T3 fibroblasts and an assessment of their involvement in bombesin-stimulation of inositol phospholipid metabolism, Oncogene, 4, 659
Chiaradonna, 2006, Ras-dependent carbon metabolism and transformation in mouse fibroblasts, Oncogene, 25, 5391, 10.1038/sj.onc.1209528
Ying, 2012, Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism, Cell, 149, 656, 10.1016/j.cell.2012.01.058
Son, 2013, Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway, Nature, 496, 101, 10.1038/nature12040
Commisso, 2013, Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells, Nature, 497, 633, 10.1038/nature12138
Lim, 2011, Macropinocytosis: an endocytic pathway for internalising large gulps, Immunol. Cell. Biol., 89, 836, 10.1038/icb.2011.20
Haq, 2013, Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF, Cancer Cell, 23, 302, 10.1016/j.ccr.2013.02.003
Scott, 2011, Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect, J. Biol. Chem., 286, 42626, 10.1074/jbc.M111.282046
Trousil, 2015, Addicted to AA (Acetoacetate): A Point of Convergence between Metabolism and BRAF Signaling, Mol. Cell, 59, 333, 10.1016/j.molcel.2015.07.024
Kang, 2015, Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling, Mol. Cell, 59, 345, 10.1016/j.molcel.2015.05.037
Kaplon, 2013, A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence, Nature, 498, 109, 10.1038/nature12154
Parsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science, 321, 1807, 10.1126/science.1164382
Mardis, 2009, Recurring mutations found by sequencing an acute myeloid leukemia genome, N. Engl. J. Med., 361, 1058, 10.1056/NEJMoa0903840
Locasale, 2011, Metabolic flux and the regulation of mammalian cell growth, Cell Metab., 14, 443, 10.1016/j.cmet.2011.07.014
Kennedy, 2010, Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation, Future Oncol., 6, 127, 10.2217/fon.09.145
van Horssen, 2013, Cancer cell metabolism regulates extracellular matrix degradation by invadopodia, Eur. J. Cell Biol., 92, 113, 10.1016/j.ejcb.2012.11.003
Cardone, 2005, The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis, Nat. Rev. Cancer, 5, 786, 10.1038/nrc1713
Lu, 2002, Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis, J. Biol. Chem., 277, 23111, 10.1074/jbc.M202487200
Colegio, 2014, Functional polarization of tumour-associated macrophages by tumour-derived lactic acid, Nature, 513, 559, 10.1038/nature13490
Vega-Naredo, 2014, Mitochondrial metabolism directs stemness and differentiation in P19 embryonal carcinoma stem cells, Cell Death Differ., 21, 1560, 10.1038/cdd.2014.66
Hamanaka, 2012, Targeting glucose metabolism for cancer therapy, J. Exp. Med., 209, 211, 10.1084/jem.20120162
Wang, 1995, Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension, Proc. Natl. Acad. Sci. U.S.A., 92, 5510, 10.1073/pnas.92.12.5510
Kaelin, 2008, Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway, Mol. Cell, 30, 393, 10.1016/j.molcel.2008.04.009
Su, 1990, Elevation of facilitated glucose-transporter messenger RNA in human hepatocellular carcinoma, Hepatology, 11, 118, 10.1002/hep.1840110120
Yamamoto, 1990, Over-expression of facilitative glucose transporter genes in human cancer, Biochem. Biophys. Res. Commun., 170, 223, 10.1016/0006-291X(90)91263-R
Nishioka, 1992, Distribution of the glucose transporters in human brain tumors, Cancer Res., 52, 3972
Xu, 2011, Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases, Cancer Cell, 19, 17, 10.1016/j.ccr.2010.12.014
Cardaci, 2012, TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State, Int. J. Cell Biol., 2012, 161837, 10.1155/2012/161837
Duvel, 2010, Activation of a metabolic gene regulatory network downstream of mTOR complex 1, Mol. Cell, 39, 171, 10.1016/j.molcel.2010.06.022
Stanton, 1991, Rapid release of bound glucose-6-phosphate dehydrogenase by growth factors. Correlation with increased enzymatic activity, J. Biol. Chem., 266, 12442, 10.1016/S0021-9258(18)98918-0
Lin, 2015, 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling, Nat. Cell Biol., 17, 1484, 10.1038/ncb3255
Horton, 2003, Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes, Proc. Natl. Acad. Sci. U.S.A., 100, 12027, 10.1073/pnas.1534923100
Hatzivassiliou, 2005, ATP citrate lyase inhibition can suppress tumor cell growth, Cancer Cell, 8, 311, 10.1016/j.ccr.2005.09.008
Chajes, 2006, Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival, Cancer Res., 66, 5287, 10.1158/0008-5472.CAN-05-1489
Vander Haar, 2007, Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40, Nat. Cell Biol., 9, 316, 10.1038/ncb1547
Shaw, 2004, The LKB1 tumor suppressor negatively regulates mTOR signaling, Cancer Cell, 6, 91, 10.1016/j.ccr.2004.06.007
Wullschleger, 2006, TOR signaling in growth and metabolism, Cell, 124, 471, 10.1016/j.cell.2006.01.016
Bar-Peled, 2014, Regulation of mTORC1 by amino acids, Trends Cell Biol., 24, 400, 10.1016/j.tcb.2014.03.003
Amelio, 2014, Serine and glycine metabolism in cancer, Trends Biochem. Sci., 39, 191, 10.1016/j.tibs.2014.02.004
Uyttenhove, 2003, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, Nat. Med., 9, 1269, 10.1038/nm934
Dillon, 2004, Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation, Cancer, 100, 826, 10.1002/cncr.20057
Komada, 1997, Apoptotic cell death of human T lymphoblastoid cells induced by arginine deiminase, Int. J. Hematol., 65, 129, 10.1016/S0925-5710(96)00538-5
Zhang, 2013, Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma, Br. J. Cancer, 109, 14, 10.1038/bjc.2013.293
Knelson, 2014, Heparan sulfate signaling in cancer, Trends Biochem. Sci., 39, 277, 10.1016/j.tibs.2014.03.001
Haimovitz-Friedman, 1997, Ceramide signaling in apoptosis, Br. Med. Bull., 53, 539, 10.1093/oxfordjournals.bmb.a011629
Ponzoni, 1995, Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation, Cancer Res., 55, 853
Li, 2015, Targeting AMPK for cancer prevention and treatment, Oncotarget, 6, 7365, 10.18632/oncotarget.3629
Chiacchiera, 2010, The AMPK-FoxO3A axis as a target for cancer treatment, Cell Cycle, 9, 1091, 10.4161/cc.9.6.11035
Morales, 2015, Metformin in cancer treatment and prevention, Annu. Rev. Med., 66, 17, 10.1146/annurev-med-062613-093128
Zhang, 2012, Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis, J. Clin. Endocrinol. Metab., 97, 2347, 10.1210/jc.2012-1267
Faller, 2015, mTORC1-mediated translational elongation limits intestinal tumour initiation and growth, Nature, 517, 497, 10.1038/nature13896
Cloughesy, 2008, Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma, PLoS Med., 5, e8, 10.1371/journal.pmed.0050008
Wick, 1957, Localization of the primary metabolic block produced by 2-deoxyglucose, J. Biol. Chem., 224, 963, 10.1016/S0021-9258(18)64988-9
Pelicano, 2006, Glycolysis inhibition for anticancer treatment, Oncogene, 25, 4633, 10.1038/sj.onc.1209597
Vlodavsky, 1994, Inhibition of tumor metastasis by heparanase inhibiting species of heparin, Invasion Metastasis, 14, 290
Ott, 2013, Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma, Invest. New Drugs, 31, 425, 10.1007/s10637-012-9862-2
Yau, 2013, A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma, Invest. New Drugs, 31, 99, 10.1007/s10637-012-9807-9